Do you know about - Drug Extends Survival for Myelofibrosis Patients
Quick Weight Loss Center Houston ! Again, for I know. Ready to share new things that are useful. You and your friends. What I said. It isn't outcome that the actual about Quick Weight Loss Center Houston . You see this article for information on anyone want to know is Quick Weight Loss Center Houston .How is Drug Extends Survival for Myelofibrosis Patients
Drug Extends Survival for Myelofibrosis Patients Tube. Duration : 4.25 Mins.We had a good read. For the benefit of yourself. Be sure to read to the end. I want you to get good knowledge from Quick Weight Loss Center Houston . A drug that relieves the severe symptoms of a life-threatening bone marrow cancer called myelofibrosis also improves the survival of patients with the disease, according to a phase III clinical trial published in the March 1 edition of New England Journal of Medicine. "The Phase I/II clinical trial showed that ruxolitinib improves quality of life for many patients with myelofibrosis and now this phase III study indicates that the drug extends survival in a patient population that has lacked effective treatments," said study principal investigator Srdan Verstovsek, MD, Ph.D., associate professor in The University of Texas MD Anderson Cancer Center Department of Leukemia. Patients who received ruxolitinib also experienced relief from the disease's debilitating symptoms, which include fatigue, weight loss, abdominal pain, severe itching, night sweats and bone pain. They were much more likely to have the drug shrink their swollen spleens, a hallmark of the disease tied to many of the symptoms. Myelofibrosis is caused by the accumulation of malignant bone marrow cells that triggers an inflammatory response, scarring the bone marrow and limiting its ability to produce blood, resulting in anemia. About 3000 new cases of myelofibrosis are diagnosed in the United States each year, Verstovsek said. Average survival ranges from two to 11 years, depending on a variety of prognostic factors. Last November, the US Food and Drug Administration approved ruxolitinib, produced by Incyte ...
No comments:
Post a Comment